Evidence map›Paper›PMID 41726610›Full record

ArticleACS omega2026

Identifying Potential BACE1 Inhibitors from the ChEMBL Database Using Machine Learning and Atomistic Simulation Approaches.

Quang Tung Dao, Thi Mai Dung Do, Quynh Mai Thai, Phuong-Thao Tran, Son Tung Ngo, Trung Hai Nguyen

Abstract read
In one paragraph

Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Quang Tung DaoDepartment of Computer and Systems Sciences, Stockholm University, Stockholm 106 91, Sweden.
Thi Mai Dung DoDepartment of Pharmaceutical Chemistry, Faculty of Pharmaceutical Chemistry and Technology, Hanoi University of Pharmacy, Hanoi 11021, Vietnam.ORCID https://orcid.org/0000-0003-3326-2464
Quynh Mai ThaiLaboratory of Biophysics, Institute for Advanced Study in Technology, Ton Duc Thang University, Ho Chi Minh City 72915, Vietnam.ORCID https://orcid.org/0000-0003-2149-5690
Phuong-Thao TranDepartment of Pharmaceutical Chemistry, Faculty of Pharmaceutical Chemistry and Technology, Hanoi University of Pharmacy, Hanoi 11021, Vietnam.ORCID https://orcid.org/0000-0003-4855-2544
Son Tung NgoLaboratory of Biophysics, Institute for Advanced Study in Technology, Ton Duc Thang University, Ho Chi Minh City 72915, Vietnam.ORCID https://orcid.org/0000-0003-1034-1768
Trung Hai NguyenLaboratory of Biophysics, Institute for Advanced Study in Technology, Ton Duc Thang University, Ho Chi Minh City 72915, Vietnam.ORCID https://orcid.org/0000-0003-1848-3963

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The inhibition of β-site amyloid precursor protein-cleaving enzyme 1 presents a promising therapeutic strategy for treating Alzheimer's disease by reducing amyloid-β (Aβ) production. This paper employed a computational approach that combined machine learning (ML) and atomistic simulations to accelerate the discovery of potential BACE1 inhibitors. Our ML models, trained on a set of ligands with experimental binding affinity, showed high accuracy when tested on a holdout test set. The best model was used to screen more than two million compounds in the CHEMBL33 chemical library to obtain a short list of top-hit compounds, which were further analyzed using molecular docking and fast pulling of ligand (FPL) simulations. The insights into structure and binding energetics obtained from FPL simulations elucidate the stability and interaction mechanisms of the BACE1-ligand bound state, providing data useful for the rational design of novel AD therapeutics.

Identifiers

PMID41726610
PMCPMC12917708

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.